Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorBasic Materials
CIKN/A
Phone45-4446-0000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.28 billion
Profitability
Miscellaneous
Employees6,427
Next Earnings Date10/23/2019 (Estimated)
OptionableNot Optionable
NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions
What is NOVOZYMES A/S/S's stock symbol?
NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."
How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S?
NOVOZYMES A/S/S announced an annual dividend on Thursday, February 7th. Shareholders of record on Friday, March 1st will be paid a dividend of $0.504 per share on Tuesday, March 19th. This represents a yield of 1.16%. The ex-dividend date of this dividend is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History.
How were NOVOZYMES A/S/S's earnings last quarter?
NOVOZYMES A/S/S (OTCMKTS:NVZMY) released its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.53 by $0.06. The biotechnology company had revenue of $520.49 million for the quarter, compared to analysts' expectations of $556.19 million. NOVOZYMES A/S/S had a net margin of 22.31% and a return on equity of 28.26%. View NOVOZYMES A/S/S's Earnings History.
When is NOVOZYMES A/S/S's next earnings date?
What is the consensus analysts' recommendation for NOVOZYMES A/S/S?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NOVOZYMES A/S/S.
Has NOVOZYMES A/S/S been receiving favorable news coverage?
Media headlines about NVZMY stock have been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NOVOZYMES A/S/S earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for NOVOZYMES A/S/S.
Who are some of NOVOZYMES A/S/S's key competitors?
Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Moderna (MRNA), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Ablynx (ABLYF) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of NOVOZYMES A/S/S own?
Who are NOVOZYMES A/S/S's key executives?
NOVOZYMES A/S/S's management team includes the folowing people:
- Mr. Peder Holk Nielsen, Pres & CEO (Age 63)
- Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)
- Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)
- Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)
- Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46)
How do I buy shares of NOVOZYMES A/S/S?
Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NOVOZYMES A/S/S's stock price today?
One share of NVZMY stock can currently be purchased for approximately $42.77.
How big of a company is NOVOZYMES A/S/S?
NOVOZYMES A/S/S has a market capitalization of $12.70 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,427 workers across the globe.View Additional Information About NOVOZYMES A/S/S.
What is NOVOZYMES A/S/S's official website?
How can I contact NOVOZYMES A/S/S?
NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]
MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)
MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
